Interleukin-1 as a therapeutic target in gout
- PMID: 25633244
- DOI: 10.1097/BOR.0000000000000143
Interleukin-1 as a therapeutic target in gout
Abstract
Purpose of review: To give an overview of current evidence for interleukin (IL)-1 blockade in the management of gout.
Recent findings: Three IL-1 blockers are currently available for clinical use: anakinra, rilonacept and canakinumab. Recent studies have focused on drugs with a long half-life: rilonacept and canakinumab. For treatment of acute gouty arthritis, three randomized controlled trials (RCTs) showed efficacy of canakinumab with some safety concerns and one RCT failed to show efficacy of rilonacept. For prevention of gout flare when starting uric acid lowering therapy (ULT), four RCTs showed efficacy of rilonacept and one RCT showed efficacy of canakinumab.
Summary: There is sufficient evidence supporting the use of IL-1 blockers for treatment of acute gouty arthritis or for prevention of gout flares when starting ULT in selected patients, with contraindications or intolerance to conventional therapy. More data are needed to assess safety and to specify their use in routine practice.
Similar articles
-
Anti-interleukin-1 therapy in the management of gout.Curr Rheumatol Rep. 2014 Feb;16(2):398. doi: 10.1007/s11926-013-0398-z. Curr Rheumatol Rep. 2014. PMID: 24407823 Review.
-
Role of interleukin-1 inhibitors in the management of gout.Pharmacotherapy. 2013 Jul;33(7):744-53. doi: 10.1002/phar.1265. Epub 2013 Apr 3. Pharmacotherapy. 2013. PMID: 23553601 Review.
-
Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy.Semin Arthritis Rheum. 2012 Oct;42(2):155-65. doi: 10.1016/j.semarthrit.2012.03.010. Epub 2012 Apr 26. Semin Arthritis Rheum. 2012. PMID: 22542277 Review.
-
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.Arthritis Care Res (Hoboken). 2012 Oct;64(10):1462-70. doi: 10.1002/acr.21690. Arthritis Care Res (Hoboken). 2012. PMID: 22549879 Clinical Trial.
-
Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.J Rheumatol. 2014 Aug;41(8):1703-11. doi: 10.3899/jrheum.131226. Epub 2014 Jul 15. J Rheumatol. 2014. PMID: 25028379 Clinical Trial.
Cited by
-
Hyperuricemia and its related diseases: mechanisms and advances in therapy.Signal Transduct Target Ther. 2024 Aug 28;9(1):212. doi: 10.1038/s41392-024-01916-y. Signal Transduct Target Ther. 2024. PMID: 39191722 Free PMC article. Review.
-
Tanshinone IIA Improves Acute Gouty Arthritis in Rats through Regulating Neutrophil Activation and the NLRP3 Inflammasome.Dis Markers. 2022 Dec 19;2022:5851412. doi: 10.1155/2022/5851412. eCollection 2022. Dis Markers. 2022. PMID: 36578443 Free PMC article.
-
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.Front Immunol. 2022 Nov 24;13:1045982. doi: 10.3389/fimmu.2022.1045982. eCollection 2022. Front Immunol. 2022. PMID: 36505444 Free PMC article.
-
Angiotensin type 2 receptor antagonism as a new target to manage gout.Inflammopharmacology. 2022 Dec;30(6):2399-2410. doi: 10.1007/s10787-022-01076-x. Epub 2022 Sep 29. Inflammopharmacology. 2022. PMID: 36173505 Free PMC article.
-
Profile of serum cytokine concentrations in patients with gouty arthritis.J Int Med Res. 2021 Nov;49(11):3000605211055618. doi: 10.1177/03000605211055618. J Int Med Res. 2021. PMID: 34772308 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials